Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2021

View Archived Issues

A different path to specificity for Ras inhibitors

Crinetics opens phase III study of paltusotine to treat acromegaly

LIB Therapeutics initiates phase III studies of lerodalcibep in hypercholesterolemia

BioNTech and Regeneron evaluate the combination of BNT-111 and cemiplimab in melanoma

Anti-CD6 therapy suppresses autoimmunity and enhances cancer cell death

Characterization of HSK-16149, a selective ligand of VGCC alpha2delta subunit

Phase I trial of a vaccine targeting tumor-associated antigens PSA, MUC-1 and brachyury in mCRPC

Adrenaline release immobilizes immune cell responses

Gene variants linked to premenstrual dysphoric disorder

IL-12 immunoconjugate SON-1010 generally well tolerated in cynomolgus monkeys

FDA clears IND application for PF-614-MPAR opioid with overdose protection

Patient dosing begins in phase Ib/II study of CFI-400945 in leukemia

European Commission approves Orladeyo for the prevention of HAE attacks

New model of metabolic syndrome-induced CKD in mice

Janssen Pharmaceutica divulges CB1 and/or CB2 receptor agonists

Esteve Pharmaceuticals patents new analgesics

Monte Rosa Therapeutics discloses new protein cereblon modulators

Heptares Therapeutics presents EP4 receptor antagonists

U.S. researchers discover new CARs against cytomegalovirus

FDA approves Farxiga for chronic kidney disease

FDA approves Ferriprox to treat transfusional iron overload due to sickle cell disease

Researchers identify new markers of treatment response in alcohol use disorder

FDA issues complete response letter for tralokinumab in moderate to severe atopic dermatitis

Synairgen reports home cohort and combined analysis from phase II trial of SNG-001 in COVID-19

Repare initiates phase I trial of oral PKMYT1 inhibitor RP-6306

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...